Lotte Biologics is set to attend DCAT Week 2026, a leading pharmaceutical and biotechnology event in New York City from March 23-26. This participation underscores Lotte Biologics’ commitment to expanding partnerships and solidifying its global presence within the Contract Development and Manufacturing Organization (CDMO) sector.
During DCAT Week, Lotte Biologics will host meetings at the Lotte New York Palace, the event’s primary location. These meetings will focus on engaging with potential collaborators and identifying new business ventures, with a particular emphasis on opportunities within the North American market.
Lotte Biologics intends to showcase the synergistic benefits of its dual-site manufacturing network: the Syracuse Bio Campus in New York and the Songdo Bio Campus in Incheon, South Korea. The Songdo facility is slated for completion in August, representing a significant milestone in the company’s global manufacturing expansion strategy.
By leveraging this strategic dual-site model spanning the US and South Korea, Lotte Biologics aims to offer global clients enhanced flexibility and reliability in their manufacturing processes.
The company will also highlight its expanding service portfolio, made possible through strategic alliances. The partnership with Asimov, a US-based cell line development expert, enables Lotte Biologics to provide comprehensive “DNA-to-drug-substance” services.
This collaboration facilitates seamless integrated development and manufacturing, drastically reducing timelines from transfection to drug substance release to approximately 8.5 months.
“DCAT Week is a pivotal event bringing together key decision-makers from across the global pharmaceutical and biotechnology landscape,” stated a representative from Lotte Biologics. “Our participation is aimed at exploring new partnership avenues and further strengthening our competitive edge in the global CDMO market.”
jwjeon7625
